Acrivon Therapeutics Files 2025 Proxy Statement
Ticker: ACRV · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1781174
| Field | Detail |
|---|---|
| Company | Acrivon Therapeutics, Inc. (ACRV) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, corporate-governance, board-of-directors
TL;DR
Acrivon's proxy statement is out, detailing exec pay & board ops for 2024. Vote wisely!
AI Summary
Acrivon Therapeutics, Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting of stockholders. The filing details the company's board of directors, executive compensation, and other corporate governance matters for the fiscal year ending December 31, 2024. Key individuals mentioned include Eric Devroe, Kristina Masson, and Peter Blume-Jensen, all serving as members of the board.
Why It Matters
This filing provides shareholders with crucial information regarding the company's leadership, compensation practices, and voting matters, enabling informed participation in corporate governance decisions.
Risk Assessment
Risk Level: low — This is a routine proxy filing, providing information to shareholders rather than announcing new material events.
Key Numbers
- 2024 — Fiscal Year End (The proxy statement covers corporate matters for the fiscal year ending December 31, 2024.)
- 20250425 — Filing Date (The definitive proxy statement was filed with the SEC on April 25, 2025.)
Key Players & Entities
- Acrivon Therapeutics, Inc. (company) — Registrant
- Eric Devroe (person) — Board Member
- Kristina Masson (person) — Board Member
- Peter Blume-Jensen (person) — Board Member
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the annual meeting, including details on board members, executive compensation, and voting matters.
Who are the named board members for Acrivon Therapeutics, Inc. in this filing?
The filing names Eric Devroe, Kristina Masson, and Peter Blume-Jensen as members of the board.
What fiscal year does this proxy statement cover?
This proxy statement covers the fiscal year ending December 31, 2024.
When was this definitive proxy statement filed with the SEC?
The definitive proxy statement was filed on April 25, 2025.
What is the company's Standard Industrial Classification (SIC) code?
Acrivon Therapeutics, Inc. has a SIC code of 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Eric Devroe regarding Acrivon Therapeutics, Inc. (ACRV).